Indivior PLC (INDV)
NASDAQ:INDV
Want to see INDV full AI Analyst Report?
INDV Stock Chart & Stats
$32.70
--
Market closed
$32.70
--
Day’s Range― - ―
52-Week Range$11.49 - $41.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.08M
Market Cap
$4.58B
Enterprise Value$5.02B
Total Cash (Recent Filing)$175.00M
Total Debt (Recent Filing)$509.00M
Price to Earnings (P/E)10.7
Beta0.69
Next Earnings
Jul 30, 2026EPS Estimate
0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.01
Shares Outstanding121,922,060
10 Day Avg. Volume1,771,159
30 Day Avg. Volume2,079,012
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-45.77
Price to Sales (P/S)3.62
P/FCF Ratio-48.23
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue3.89
Enterprise Value/Gross Profit4.68
Enterprise Value/Ebitda11.10
Forecast
1Y Price Target
$52.33Price Target Upside60.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)3.49
Revenue Forecast (FY)$1.23B
Bulls Say, Bears Say
Bulls Say
Market-leading OUD Franchise (SUBLOCADE)SUBLOCADE's strong, recurring injectable model with rapid new patient growth and expanding prescriber base supports durable revenue visibility. Monthly depot dosing fosters stickier demand and repeat revenue, reducing churn risk and underpinning the company's core commercial moat over the next 2–6 months.
Sustained Margin Expansion And EBITDA StrengthMaterial operating leverage and cost rationalization drove record EBITDA and management is guiding to much higher margins, implying structurally improved profitability. Higher gross margins and disciplined OpEx create a stronger cash-profit conversion profile if execution and dispense yields remain consistent.
Balance-sheet And Capital-structure ImprovementRefinancing to very low coupon convertible notes and prepaying higher-cost term debt materially lowers interest expense and covenant pressure, increasing financial flexibility. Executing buybacks while refinancing indicates confidence and preserves liquidity optionality for operations or M&A over the medium term.
Bears Say
Negative Stockholders' EquityNegative shareholders' equity is a material structural balance-sheet issue that can limit financial flexibility, complicate debt/equity metrics and investor perception, and constrain strategic options if adverse events occur. It remains a multi-quarter governance and capital-risk overhang.
Weak Recent Cash ConversionDespite accounting profitability, negative operating and free cash flow indicate working-capital strain or timing effects that can erode liquidity and force reliance on external financing. This undermines the durability of reported earnings unless cash conversion normalizes sustainably.
Pipeline Setbacks And R&D ContractionHalting two programs and shrinking R&D reduces future product diversification, increasing revenue concentration risk on SUBLOCADE. Longer-term growth now depends more on commercial execution and BD deals, making organic pipeline-driven upside less likely in the medium term.
Indivior News
INDV FAQ
What was Indivior PLC’s price range in the past 12 months?
Indivior PLC lowest stock price was $11.49 and its highest was $41.00 in the past 12 months.
What is Indivior PLC’s market cap?
Indivior PLC’s market cap is $4.58B.
When is Indivior PLC’s upcoming earnings report date?
Indivior PLC’s upcoming earnings report date is Jul 30, 2026 which is in 64 days.
How were Indivior PLC’s earnings last quarter?
Indivior PLC released its earnings results on Apr 30, 2026. The company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.3.
Is Indivior PLC overvalued?
According to Wall Street analysts Indivior PLC’s price is currently Undervalued.
Does Indivior PLC pay dividends?
Indivior PLC does not currently pay dividends.
What is Indivior PLC’s EPS estimate?
Indivior PLC’s EPS estimate is 0.83.
How many shares outstanding does Indivior PLC have?
Indivior PLC has 121,922,060 shares outstanding.
What happened to Indivior PLC’s price movement after its last earnings report?
Indivior PLC reported an EPS of $0.96 in its last earnings report, beating expectations of $0.66. Following the earnings report the stock price went up 7.701%.
Which hedge fund is a major shareholder of Indivior PLC?
Currently, no hedge funds are holding shares in INDV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Indivior Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.33 (60.04% Upside)
$52.33 (60.04% Upside)
Blogger Sentiment
Bullish
INDV Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $31.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 8.4%
Last 30 Days ▲ 8.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
235.79%
12-Months-Change
Fundamentals
Return on Equity
-142.01%
Trailing 12-Months
Asset Growth
-12.95%
Trailing 12-Months
Company Description
Indivior PLC
Indivior Pharmaceuticals Inc is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.
INDV Company Deck
INDV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial execution and substantial financial improvement driven by SUBLOCADE (double-digit revenue growth, 20% dispense unit growth, record adjusted EBITDA up 112% and raised 2026 guidance). It also announced disciplined capital actions that improve the balance sheet and return capital to shareholders. Offsetting these positives were setbacks in early-stage R&D (INDV-6001 and INDV-2000 not advancing internally), expected gross-to-net pressure for 2026, and ongoing reliance on SUBLOCADE for growth. On balance, the favorable commercial and financial momentum and upgraded guidance materially outweigh the program setbacks and known headwinds.View all INDV earnings summariesINDV Stock 12 Month Forecast
Average Price Target
$52.33
▲(60.04% Upside)
Technical Analysis
Neurocrine
―
Supernus Pharmaceuticals
―
Teva Pharmaceutical
―
Collegium Pharmaceutical
―
Amneal Pharmaceuticals
―
Ownership Overview
0.81% Insiders
7.46% Mutual Funds
30.86% Other Institutional Investors
34.14% Public Companies and Individual Investors